Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprubart in kidney transplant recipients
NCT06126380Phase 2Enrolling by invitation
- Sponsor
- Eledon Pharmaceuticals, Inc.
- Start
- Oct 2023
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of tegoprubart in kidney transplant rejection, sponsored by Eledon Pharmaceuticals, Inc.. Started Oct 2023; status: enrolling by invitation.
02
Drugs
tegoprubart
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT06126380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126380.